Atlas Trials

A Multicenter Open-Label Treatment Protocol to Observe the Safety of Replagal (Agalsidase Alfa) Enzyme Replacement Therapy in Canadian Patients With Fabry Disease

Clinical trial NCT01298141 · COMPLETED

Trial details

NCT number
NCT01298141
Sponsor
Shire
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
Fabry Disease
Start date
2011-08-10
Primary completion
2017-09-25
Enrollment
171

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.